|Posted: Feb 21, 2017|
Ligand-baited nanosprings capture tumor-derived exosomes from a prostate cancer cell line(Nanowerk News) In a new paper in Springer's Journal of Materials Science ("Silica nanostructured platform for affinity capture of tumor-derived exosomes"), researchers at Washington State University report a new approach for the effective capture of tumor-derived exosomes from a prostate cancer cell line. Exosomes are small secreted vesicles that play a key role in intercellular communication and cancer progression.
|Figure a shows captured exosomes on ligand-baited nanosprings, the exosomes are indicated by the arrows. Figure b shows a TEM image of captured exosomes following negative staining with phosphotungstic acid (PTA) PH = 7.1. (© Springer)|
|Developing effective and high-throughput selective capture technology for exosomes bearing the prostate-specific membrane antigen (PSMA) biomarker is critical for early diagnostic and prognostic evaluation of prostate cancer and treatment planning. It is known that the prostate tumor enzyme-biomarker PSMA is highly enriched in exosomes secreted by PSMA+ prostate cancer cells.|
|A novel biofunctionalized silica nanostructure was designed to selectivity capture tumor-derived exosomes through the interaction of a known PSMA ligand with the PSMA on the exosomes.|
|This work enables a non-invasive approach for diagnosis and prognosis of prostate cancer. It overcomes many of the limitations of alternative approaches that are often ineffective in isolating tumor-derived exosomes from those derived from normal tissue because of the low recovery yields and the time required for the process.|
|The concept was demonstrated using a single cancer type (i.e., prostate cancer), but based on the data presented in this study, the authors expect that a broad panel of biomarker ligands can be baited on the silica nanostructures to selectively capture biomarker-positive exosomes from an array of cell types.|
|Further advantages of the approach used in this study are the ability to isolate a specific subpopulation of exosomes relying on the expression of a specific surface marker as well as improved exosome recovery rate. In the future, the authors envision a microfluidic flow device that will allow for increased exosome capture efficiency and clinical applications.|
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: